LY3962673 for KRAS G12D-mutated solid tumors - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called LY3962673 (the study drug) is a safe and effective option for cancer that has a KRAS G12D mutation. We are also trying to find the best dose level to use.
What is the Condition Being Studied?
Solid Tumors with KRAS G12D Mutation
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with a solid tumor form of cancer
- Have disease that is inoperable, advanced, or metastatic
- The tumor tests positive for a KRAS G12D mutation
For more information, contact the study team at dana.a.warren@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Take the study drug by mouth once or twice every day
- Depending on which arm of the study you are in, you may also get standard anti-cancer drugs every 1 to 2 weeks
- Have your tumor biopsied
- Give blood and urine samples
- Have regular CT or MRI scans
Study Details
Full Title
[J5J-OX-JZZA] A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00116471
NCT:
NCT06586515
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu